Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study

References

• Lee DY, Lee JH, Ju YS, et al. The prevalence of dementia in older people in an urban population of Korea: the Seoul study. J Am Geriatr Soc 2002;50:1233-9
   PubMed Web of Science ®Google Scholar
• Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;CD005593. doi:10.1002/14651858
   PubMed Web of Science ®Google Scholar
• Frankiewicz T, Parsons CG. Memantine restores long term potentiation impaired by tonic N-methyl-D-aspartate (NMDA) receptor activation following reduction of Mg2+ in hippocampal slices. Neuropharmacology 1999;38:1253-9
   PubMed Web of Science ®Google Scholar
• Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate–severe Alzheimer's disease. N Engl J Med 2006;348:1333-41
   Google Scholar
• McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006;CD003154
   Google Scholar
• Lockhart IA, Mitchell SA, Kelly S. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the ‘real-world’ evidence. Dement Geriatr Cogn Disord 2009;28:389-403
   PubMed Web of Science ®Google Scholar
• Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009;80:600-7
   PubMed Web of Science ®Google Scholar
• Vidal JS, Lacombe JM, Dartigues JF, et al. Memantine therapy for Alzheimer disease in real-world practice: an observational study in a large representative sample of French patients. Alzheimer Dis Assoc Disord 2008;22:125-30
   PubMed Web of Science ®Google Scholar
• Tariot PN, Farlow MR, Groosberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA 2004;291: 317-24
   PubMed Web of Science ®Google Scholar
• Dantoine T, Auriacombe S, Sarazin M, et al. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract 2006;60:110-18
   PubMed Web of Science ®Google Scholar
• Olin JT, Bhatnagar V, Reyes P, et al. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32). Int J Geriatr Psychiatry 2010;25:419-26
   PubMed Web of Science ®Google Scholar
• Riepe MW, Adler G, Ibach B, et al. Adding memantine to rivastigmine therapy in patients with mild-to-moderate Alzheimer's disease: results of a 12-week, open-label pilot study. J Clin Psychiatry 2006;8:258-63
   Google Scholar
• Porsteinsson AP, Grossberg GT, Mintzer J, et al. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008;5:83-9
   PubMed Web of Science ®Google Scholar
• Oertel W, Ross JS, Eggert K, et al. Rationale for transdermal drug administration in Alzheimer disease. Neurology 2007;69(4 Suppl. 1):S4-9
   PubMed Web of Science ®Google Scholar
• Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease – rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007;22:456-67
   PubMed Web of Science ®Google Scholar
• Farlow MR, Alva G, Meng X, et al. 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. Curr Med Res Opin 2010;26:263-9
   PubMed Web of Science ®Google Scholar
• Jones RW. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int J Geriatr Psychiatry 2010;25:547-53
   PubMed Web of Science ®Google Scholar
• McKhann G, Drachman D, Folstein M, et al. Clinical Diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44
   PubMed Web of Science ®Google Scholar
• Kang Y, Na DL, Hahn S. A validity study on the Korean Mini-Mental State Examination K-MMSE) in dementia patients. J Korean Neurol Assoc 1997;15:300-7
   Google Scholar
• Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64
   PubMed Web of Science ®Google Scholar
• Dubois B, Slachevsky A, Litvan I, et al. Pillon B. A Frontal Assessment Battery at bedside. Neurology 2000;55:1621-6
   PubMed Web of Science ®Google Scholar
• Kang SJ, Choi SH, Lee BH, et al. Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI). J Geriatr Psychiatry Neurol 2004;17:32-5
   PubMed Web of Science ®Google Scholar
• Suh GH. Agitated behaviours among the institutionalized elderly with dementia: validation of the Korean version of the Cohen–Mansfield Agitation Inventory. Int J Geriatr Psychiatry 2004;19:378-85
   PubMed Web of Science ®Google Scholar
• Choi SH, Na DL, Lee BH, et al. Dementia Research Group. Estimating the validity of the Korean version of Expanded Clinical Dementia Rating (CDR) scale. J Korean Neurol Assoc 2001;19:585-91
   Google Scholar
• Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's Disease. Alzheimer Dis Assoc Disord 1997;11(Suppl. 2):S33-9
   PubMed Web of Science ®Google Scholar
• Ramnes G, Danysz W, Parsons CG. Pharmacodynamics of memantine: an update. Curr Neuropharmacol 2008;6:55-78
   PubMed Web of Science ®Google Scholar
• Olney JW. The neurotoxicity of NMDA receptor antagonists: an overview. Psychopharmacol Bull 1994;30:533-40
   PubMed Web of Science ®Google Scholar
• Creeley CE, Wozniak DF, Nardi A, et al. Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain. Neurobiol Aging 2008;29:153-67
   PubMed Web of Science ®Google Scholar
• Aracava Y, Pereira EF, Maelicke A, et al. Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther 2005;312:1195-205
   PubMed Web of Science ®Google Scholar
• Cummings JL, Schneider LS, Tariot PN, et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006;67:57-63
   PubMed Web of Science ®Google Scholar
• Ballard C, Margallo-Lana M, Juszczak E, et al. Qetiapine and rivastigmine and cognitive decline on Alzheimer's disease: randomized double blind placebo controlled trial. BMJ 2005;330:874
   PubMed Web of Science ®Google Scholar